Sex differences in high-potency P2Y12 inhibitors prescription among patients with acute myocardial infarction
Hend Mansoor1, Remy Poudel2, Haoyun Hong2
1Pharmacy Practice and Science Department, University of Kentucky, Lexington, KY, United States of America.
Background:
Sex differences in the outcomes of patients with acute myocardial infarction (AMI) persist and could be related to the differences in management including high-potency P2Y12 inhibitors.
Methods:
Patients with AMI undergoing percutaneous coronary intervention (PCI) from the American Heart Association Get With The Guidelines®-Coronary Artery Disease Registry between October 2019 to December 2022 were included. Multivariable hierarchical models were used to assess whether there are differences in high-potency P2Y12 inhibitors (i.e., ticagrelor or prasugrel) prescription at discharge adjusting for race/ethnicity, insurance, age, social vulnerability index (SVI), zip code designation, and medical history.
Results:
Among 131,153 patients with AMI who underwent PCI, 59.8 % were discharged on a high-potency P2Y12 inhibitor. Compared with men, women were less likely prescribed a high-potency P2Y12 inhibitor (57.6 % vs 63.1 %), and this pattern did not change during the study period. Among women, the likelihood of high-potency P2Y12 inhibitors prescription was not significantly different across different race/ethnicities. However, in men, non-Hispanic Blacks and Hispanics had lower odds of high-potency P2Y12 inhibitors prescription compared with non-Hispanic Whites among men. The SVI was not independently associated with high-potency P2Y12 inhibitors in women or men.
Conclusions:
In this large contemporary observational analysis of patients with AMI undergoing PCI, women irrespective of race/ethnicity were less likely prescribed a high-potency P2Y12 inhibitor upon discharge. These associations were not influenced by social determinants of health as reflected by the SVI. These findings highlight an opportunity for continued education and dissemination to optimize antiplatelet therapy selection to improve outcomes among AMI patients undergoing PCI.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Coronary Artery Disease V: Interprofessional Care
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...